FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223977417> ?p ?o ?g. }

• W4223977417 endingPage "1317" @default.
• W4223977417 startingPage "1305" @default.
• W4223977417 abstract "To explore the healthcare resource utilization (HCRU) and costs for patients with progressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with [177Lu]Lu-DOTA-TATE and matched patients treated with somatostatin analogs (SSAs), chemotherapy, or targeted therapies.Hospital Episode Statistics (HES) dataset 2016-2018 was used to compare HCRU and costs between the two cohorts. The [177Lu]Lu-DOTA-TATE cohort included patients assigned with a diagnosis code relevant to GEP-NET, a procedure code for imaging or SSAs, and a subsequent code for radionuclide therapy. The non-[177Lu]Lu-DOTA-TATE cohort included patients assigned with a diagnosis code relevant to GEP-NET who had an increased frequency of SSAs or switched from SSAs to chemotherapy or targeted therapies. Cohorts were matched on propensity scores with sex, age at disease progression, and Charlson Comorbidity Index as parameters. Healthcare Resource Group codes were used for costing.A total of 199 matched patients were included. The [177Lu]Lu-DOTA-TATE cohort had lower overall costs (£1,882,028 vs. £3,016,321; p < .0001), non-elective inpatient spells (289 vs. 611 days) and costs (£849,569 vs. £1,707,109; p < .0001 for both), Accident & Emergency costs (£41,978 vs. £62,480; p = .0013), and average length of stay for overall inpatient spells (14.2 vs. 23.3 days; p = .1092) compared with the non-[177Lu]Lu-DOTA-TATE cohort.These analyses indicate significantly lower overall costs and HCRU for progressive GEP-NET patients treated with [177Lu]Lu-DOTA-TATE. Current research reveals that future real-world analyses would further benefit from using additional databases linked to the HES dataset such as the Clinical Practice Research Datalink and/or National Cancer Registration and Analysis Service database.Neuroendocrine neoplasms (NENs) are uncommon cancers involving the body's neuroendocrine cells. One type of NEN that is less aggressive with more favorable characteristics and prognosis is known as neuroendocrine tumor (NET). Somatostatin receptors (SSTR) are expressed by most NETs and are important treatment targets. Two-thirds of NETs originate in the body's gastroenteropancreatic system (GEP-NETs). GEP-NET is typically treated in the first instance with somatostatin analogs (SSAs), while other treatments such as chemotherapy, biologic targeted therapy, or Radio Ligand Therapy (RLT), can be offered to patients who have progressed. [177Lu]Lu-DOTA-TATE is a form of RLT that has recently been approved for use in England, Wales, and Scotland.The purpose of this study is to analyze the utilization of healthcare resources and the costs associated with the management of GEP-NETs patients who have progressed on SSAs. This study is based on hospital data from England as available in the Hospital Episode Statistics dataset 2016–2018.The utilization and costs of healthcare resources were compared between two groups of patients. Following progression, one group received [177Lu]Lu-DOTA-TATE, while the other group received other therapies (chemotherapy, biologic targeted therapy, or SSA with escalated or more frequent dosing). Statistical techniques were applied to enhance the comparability of analyzed groups of patients.The results revealed that the [177Lu]Lu-DOTA-TATE group had lower inpatient admissions, outpatient appointments, and Accident & Emergency attendances compared with the non-[177Lu]Lu-DOTA-TATE group. Furthermore, the overall costs in the [177Lu]Lu-DOTA-TATE group were lower by 37.6%. This study indicated that patients and hospitals in England and other parts of the United Kingdom may benefit from the use of [177Lu]Lu-DOTA-TATE. Further research is foreseen involving additional and linked databases, including further clinical outcomes as well." @default.
• W4223977417 created "2022-04-19" @default.
• W4223977417 creator A5013107841 @default.
• W4223977417 creator A5051973061 @default.
• W4223977417 creator A5057160008 @default.
• W4223977417 creator A5065079366 @default.
• W4223977417 creator A5074048498 @default.
• W4223977417 date "2022-04-26" @default.
• W4223977417 modified "2023-09-27" @default.
• W4223977417 title "Real-world comparison of healthcare resource utilization and costs of [¹⁷⁷Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the hospital episode statistics dataset" @default.
• W4223977417 cites W1594294799 @default.
• W4223977417 cites W1961229376 @default.
• W4223977417 cites W1967091631 @default.
• W4223977417 cites W2016403661 @default.
• W4223977417 cites W2019607817 @default.
• W4223977417 cites W2061848583 @default.
• W4223977417 cites W2071851324 @default.
• W4223977417 cites W2075188110 @default.
• W4223977417 cites W2101266491 @default.
• W4223977417 cites W2115686439 @default.
• W4223977417 cites W2135049144 @default.
• W4223977417 cites W2137142564 @default.
• W4223977417 cites W2150291618 @default.
• W4223977417 cites W2154183223 @default.
• W4223977417 cites W2158460222 @default.
• W4223977417 cites W2158474413 @default.
• W4223977417 cites W2159805452 @default.
• W4223977417 cites W2165062498 @default.
• W4223977417 cites W2209368665 @default.
• W4223977417 cites W2260411483 @default.
• W4223977417 cites W2573369749 @default.
• W4223977417 cites W2589764398 @default.
• W4223977417 cites W2597503617 @default.
• W4223977417 cites W2607151521 @default.
• W4223977417 cites W2608160487 @default.
• W4223977417 cites W2754131662 @default.
• W4223977417 cites W2766513655 @default.
• W4223977417 cites W2775871642 @default.
• W4223977417 cites W2805387445 @default.
• W4223977417 cites W2900478373 @default.
• W4223977417 cites W2981961317 @default.
• W4223977417 cites W3006668619 @default.
• W4223977417 cites W3015314028 @default.
• W4223977417 cites W3089939587 @default.
• W4223977417 cites W3096453249 @default.
• W4223977417 cites W3120102782 @default.
• W4223977417 cites W3196206542 @default.
• W4223977417 cites W3202740622 @default.
• W4223977417 cites W4225418351 @default.
• W4223977417 cites W4225880044 @default.
• W4223977417 cites W4226027666 @default.
• W4223977417 doi "https://doi.org/10.1080/03007995.2022.2065146" @default.
• W4223977417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35418254" @default.
• W4223977417 hasPublicationYear "2022" @default.
• W4223977417 type Work @default.
• W4223977417 citedByCount "0" @default.
• W4223977417 crossrefType "journal-article" @default.
• W4223977417 hasAuthorship W4223977417A5013107841 @default.
• W4223977417 hasAuthorship W4223977417A5051973061 @default.
• W4223977417 hasAuthorship W4223977417A5057160008 @default.
• W4223977417 hasAuthorship W4223977417A5065079366 @default.
• W4223977417 hasAuthorship W4223977417A5074048498 @default.
• W4223977417 hasConcept C126322002 @default.
• W4223977417 hasConcept C143998085 @default.
• W4223977417 hasConcept C2779066768 @default.
• W4223977417 hasConcept C2989005 @default.
• W4223977417 hasConcept C2993559085 @default.
• W4223977417 hasConcept C71924100 @default.
• W4223977417 hasConcept C72563966 @default.
• W4223977417 hasConceptScore W4223977417C126322002 @default.
• W4223977417 hasConceptScore W4223977417C143998085 @default.
• W4223977417 hasConceptScore W4223977417C2779066768 @default.
• W4223977417 hasConceptScore W4223977417C2989005 @default.
• W4223977417 hasConceptScore W4223977417C2993559085 @default.
• W4223977417 hasConceptScore W4223977417C71924100 @default.
• W4223977417 hasConceptScore W4223977417C72563966 @default.
• W4223977417 hasIssue "8" @default.
• W4223977417 hasLocation W42239774171 @default.
• W4223977417 hasLocation W42239774172 @default.
• W4223977417 hasOpenAccess W4223977417 @default.
• W4223977417 hasPrimaryLocation W42239774171 @default.
• W4223977417 hasRelatedWork W2085666879 @default.
• W4223977417 hasRelatedWork W2099478219 @default.
• W4223977417 hasRelatedWork W2102381370 @default.
• W4223977417 hasRelatedWork W2157129652 @default.
• W4223977417 hasRelatedWork W2332637465 @default.
• W4223977417 hasRelatedWork W2900733241 @default.
• W4223977417 hasRelatedWork W3108679216 @default.
• W4223977417 hasRelatedWork W3138192141 @default.
• W4223977417 hasRelatedWork W4200349607 @default.
• W4223977417 hasRelatedWork W4206238483 @default.
• W4223977417 hasVolume "38" @default.
• W4223977417 isParatext "false" @default.
• W4223977417 isRetracted "false" @default.
• W4223977417 workType "article" @default.